Lazy off-take for anti-AIDs drug trial :: Mmegi Online

FRANCISTOWN: The co-principal investigator of the HIV/AIDS research organisation, Botusa (Botswana USA), Dr. Poloko Kebaabetswe says since the Truvada trials began in March this year, only 142 out of the 600 people who were screened were enrolled because the majority were HIV positive.

Truvada is an antiretroviral pill which is a combination of ARVs Tenovovir (TDF) and Emtricitabine (FTC). Botusa is doing the study to determine if taking the pill once daily can protect healthy young adults against HIV infection.

"The reason that more people did not enrol for the study is because they failed the screening test that includes the kidney and the liver. But mostly HIV accounted for most failures. Our target number of participants is 1,200 but in order to get that number about six to seven thousand people will have to be screened.

Already have an active account? Log in here.

Or Sign up and get unlimited access to premium articles.

Explore

More

Lazy off-take for anti-AIDs drug trial

FRANCISTOWN: The co-principal investigator of the HIV/AIDS research organisation, Botusa (Botswana USA), Dr. Poloko Kebaabetswe says since the Truvada trials began in March this year, only 142 out of the 600 people who were screened were enrolled because the majority were HIV positive.

Memorial service for former BFA CEO

Bishop Rebello to be buried tomorrow

Anglo exit: What it means for Botswana

GU winner as teams lose points for January 'revolt'

Botswana buys 95 heifers, 150 dairy goats from Australia

TransUnion sees more debt pressure on consumers

Gov't not on buying spree – Masisi

I'm not a fugitive – Khama

Women unite for progress